Progestational drugs
Executive Summary
FDA is proposing to withdraw the boxed warning in labeling for progestational drug products due to lack of scientific data supporting associations between the drugs and an increased risk of birth defects during the first four months of pregnancy. The agency said that the diversity of the drugs described as progestational and the variety of conditions for which they are administered "make it inappropriate to consider these drugs a single class for labeling purposes." The regulation requiring patient and physician warnings was finalized in 1978
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth